Take the challenge. CPT: 20611-LT, J7325-EJ ICD-10: M17.12, E66.01, Z68.41 CPT: 99213 ICD-10: M1a.0710, M05.79 History—The history of present illness was extended. The review of systems was extended, and two past family social history elements were documented. This makes the history level detailed. Examination—Five systems were examined. This makes the exam level detailed. Medical decision…
Reminder: MIPS Reporting Deadline Is April 2
Don’t forget: The submission window for the Quality Payment Program Performance Year 2018 closes on Tuesday, April 2, 2019. Submissions must be complete by 8:00 PM EDT. We encourage all MIPS-eligible clinicians to double-check their status and final scores with the CMS by logging into their EIDM account. Not sure how to review your final score?…
Safety Risk with Higher Dose Tofacitnib
According to the FDA, an ongoing safety trial found higher dose tofacitinib increased the risks of pulmonary embolism and death in RA patients…
Rheumatoid Arthritis Risk Lower Among Smokers Who Quit
(Reuters Health)—Adults who quit smoking decades ago may have a lower risk of rheumatoid arthritis (RA) than people who gave up cigarettes more recently, a U.S. study suggests. Smoking has long been linked to an increased risk of RA, and quitting can reduce this risk. But the new study offers fresh evidence that years of…
Tainted Research Repeatedly Re-Used to Assess Drug Effectiveness
(Reuters Health)—A new study shows how fake news—specifically, information about scientific research that may be tainted by fraud—keeps getting spread through the medical literature, misleading doctors about the safety and effectiveness of the drugs they prescribe. At issue is the failure of medical journals to flag research that’s been identified by the U.S. Food and…
Clinicians’ Use of ‘Safer’ Opioid-Prescribing Practices Spotty
NEW YORK (Reuters Health)—Many U.S. clinicians aren’t following risk-mitigation practices for opioid prescribing, new findings show. “In response to this national opioid crisis, consensus-based safer opioid prescribing guidelines have been published and state laws regulating opioid prescribing practices have been enacted,” Daniel P. Alford, MD, of Boston University School of Medicine, and colleagues write in…
U.S. FDA Chief Gottlieb Resigns
WASHINGTON (Reuters)—U.S. Food and Drug Administration (FDA) Chief Scott Gottlieb said he plans to step down in a month, calling into question how the agency will handle critical issues, such as e-cigarette use among teens and efforts to increase competition in prescription drugs. The U.S. Department of Health and Human Services (HHS), which oversees the…
ACR Addresses the Rheumatology Workforce Shortage
Analysis of the 2015 ACR Workforce Study, published in the April 2018 issue of Arthritis Care & Research, revealed the U.S. will face a shortage of 4,000 rheumatology providers by 2030.1 This shortage will be uneven, with rheumatology providers concentrated in urban and suburban areas, and rural areas underserved. The Central U.S., Southwest, Southeast and…
Practices Now Contributing to RheumPAC
Last year the ACR’s nonpartisan political action committee, RheumPAC, raised nearly $150,000 from individual contributors. Starting in 2019, the addition of the RheumPAC Advocacy Fund, where rheumatology practices and state societies can contribute corporate dollars, is expected to support RheumPAC fundraising efforts in an effort to surpass this dollar amount, giving rheumatology an even stronger…
Why Fellows Should Care about Advocacy
As a physician, I am an advocate. I am an advocate for my patients individually and collectively, and I am an advocate for my field: pediatric rheumatology. My own experiences as a patient drive me to integrate my patients’ perspectives into my medical decision making, and although my academic training has prepared me to best…
- « Previous Page
- 1
- …
- 277
- 278
- 279
- 280
- 281
- …
- 814
- Next Page »